Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery

Launched by THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO · Oct 8, 2009

Keywords

ClinConnect Summary

This clinical trial is studying how certain factors in the body affect insulin secretion in patients who have undergone Roux-en-Y gastric bypass (RYGB) surgery. RYGB is a type of weight loss surgery that has been found to improve blood sugar control in people with type 2 diabetes, even before they lose significant weight. However, some patients later experience dangerously low blood sugar levels, known as hypoglycemia. The researchers want to understand how hormones from the gut, particularly one called GLP-1, and changes in nerve activity might influence insulin production in these patients.

To participate in this trial, individuals must be between the ages of 65 and 74 and meet certain health conditions. Eligible participants include those who have experienced low blood sugar after RYGB surgery, asymptomatic individuals who have had bariatric surgery, and healthy people without a history of diabetes. Participants will need to visit the Cedars-Sinai Medical Center for evaluations. The study aims to gather important information about how RYGB affects insulin and could provide insights that help improve care for patients experiencing hypoglycemia after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Hypoglycemic RYGB patients with documented blood glucose level \<50 mg/dl
• • Asymptomatic individuals with bariatric surgery
• • Healthy non-surgical patients with no personal history of diabetes
• • Subjects must physically be able to come to our clinical research center at Cedars-Sinai Medical Center
• Exclusion Criteria:
• • Active heart, lung, liver, gastrointestinal or kidney disease; unable to give informed consent; pregnancy; uncontrolled high blood pressure or high cholesterol; significant anemia (hemoglobin \<11g/dL); prisoners or institutionalized individuals; type 2 diabetes melitis; development of any serious medical or psychiatric illness during recruitment or studies;
• • RYGB patients will also be disqualified if they have gastric outlet obstruction or severe diarrhea
• • Healthy non-surgical patients with personal history of diabetes
• For administration of atropine, the following exclusions also apply:
• • History of glaucoma
• • Uncontrolled hypertension (any subjects with BP\>140/90 and history of dyslipidemia
• • Taking any medication that might interact with atropine and cannot be stopped will be excluded from the study)
• • Myasthenia gravis
• • Brain pathology
• • Enlarged prostate in men